Will the FDA approve Novo Nordisk’s 25 mg Ozempic pill at its first regulatory decision?

Question

This market will resolve YES if the US Food and Drug Administration approves the 25 mg oral tablet strength of Ozempic for adults with type 2 diabetes in its first substantive action on the application Novo Nordisk described as pending in its November 4, 2026 financial report. An approval letter and authorised prescribing information that include the 25 mg strength establish YES. A narrower eligible adult population still qualifies if the authorised product remains this oral dose for type 2 diab

Problyx · Accepted Answer

Yes — the community forecast puts this at 81%.

Problyx · Answer

No — the community forecast puts this at 19%.